We combine precise analytics with novel statistical methodologies to overcome historically persistent barriers to powerful clinical trials.

We bring together multiple disciplines and adaptive research design skills to enable rapid project completion and translation into clinical practice, expediting the benefit for patients.

Well-established clinical, scientific and implementation leaders bring unique adaptive capabilities. Our diverse staff of technology developers and specialists includes statisticians, radiographers and engineers.

Commercial track record

The Titan team has worked on a series of successful collaborative projects with major commercial and institutional partners including:

  • Canon Toshiba
  • Rudder Group
  • Australian Stroke Alliance (a national digital platform),
  • Melbourne Brain Centre (two mobile stroke ambulances),
  • The Victorian Stroke Telemedicine reconfiguration project (with Ambulance Victoria).

Other commercial engagements include SME advisory expertise to clinical imaging start-ups looking to develop brain devices.

View our projects and clients


To transform clinical research across Australia 
and internationally.


Innovation, precision, collaboration, diversity 
and sustainability


To develop advanced brain imaging and digital health technologies to radically transform patient outcomes and deliver sustained health economic benefits.


Professor Mark Parsons


Mark Parsons is an internationally recognised neurologist and leader in stroke medicine. He is the Executive Director of Maridulu Budyari Gumal - the Sydney Partnership for Health, Education, Research and Enterprise (SPHERE).

Mark Parsons
Titan Director

He was appointed as a Professor of Medicine and Neurology at UNSW South Western Sydney Clinical School and Liverpool Hospital in 2020.

Previously, he was the Royal Melbourne Hospital Professorial Chair of Neurology at the University of Melbourne, and the Director of the Department of Neurology, Royal Melbourne Hospital. He is also a Conjoint Professor of Neurology at the University of Newcastle and a Visiting Professor at Fudan University, Shanghai. Mark was elected as a Fellow to the prestigious Australian Academy of Health and Medical Scientists (FAHMS) in 2019.

Mark is an international leader in Stroke clinical trials and brain imaging. He has considerable industry collaborations and serves on international and national advisory boards for several multinational companies.

Professor Parsons has an impressive history of achievement in implementing and translating his research into clinical practice change. The results of his work have led to major changes in health policy, clinical practice, and patient outcomes. Mark has broad experience in clinical trial design and implementation, being a principal investigator of the TASTE trial and the international stroke registry INSPIRE.
His performance and success in these areas stand him in good stead for his role as co-founder and Director of Titan Neuroscience Trials Australia.

Dr Damien Easton


Damien Easton is an experienced executive in the clinical research and government sectors with over a decade of success in leading complex medical research programs and organisations.

Damien Easton
Titan Director

Damien was the founding CEO of the Stroke Alliance (2020-2022), bringing together an unprecedented cross-sector health technology partnership of over 41 partners in stroke, digital health, aeromedical and paramedic emergency services, materials and aerospace engineering, rural health agencies and portable brain imaging. He led the record-breaking $40m MRFF Stroke Golden Hour grant application with co-chairs Profs Stephen Davis and Geoffrey Donnan, awarded in 2021. He is the Chief Strategy Officer for the Stroke Alliance where he brings a well-established professional reputation as a trusted advisor to other executives, clinician and academic leaders, government advisors, philanthropists, and senior bureaucrats.

Damien is also Director of Strategy and Operations at the Melbourne Brain Centre, Royal Melbourne Hospital where he oversees strategic planning for clinical research activities. He has led the development of new stroke ambulance operations, commencing with the implementation of Australia’s first Mobile Stroke Unit (stroke ambulance) which has now attended over 5000 patients in metro Melbourne.

His exceptional stakeholder engagement and project management expertise has been critical in securing high-value partnerships and building interdisciplinary, cross-organisational collaborations. He has led bid development with over $235 million in successful competitive funding, including multiple record-breaking research grants with an 86% success rate, nearly 10 times the national average.

Associate Professor Andrew Bivard


Andrew Bivard is a leading neuroscience researcher with a highly competitive track record of research translation, having implemented perfusion imaging 
at over 70 hospitals around the world and more 
that 40 in Australia.

Andrew Bivard
Associate Professor

Andrew is head of the neuroimaging group at the Melbourne Brain Centre, Royal Melbourne Hospital. He is the technology lead for the Australian Stroke Alliance’s telestroke platform.

His work in acute ischaemic stroke imaging focusses on patient selection for reperfusion therapies to maximise benefits and limit potential harms.

Andrew has built a strong partnership with Siemens Healthineers to co-develop and implement Computed Tomography Perfusion (CTP) imaging capabilities.

Stan Skafidas

Chair, Commercial and Strategic 
Advisory Committee

Stan Skafidas is Titan’s chair of its Scientific Advisory committee. He leads the Melbourne School of Engineering’s research in nanoelectronics.

Stan Skafidas

Stan plays a critical role on the Australian Stroke Alliance’s Industry Engagement Council and Commercialisation committee. Stan has an exemplary commercial track record as a founder and inventor.

He has over 300 publications in the fields of nanoelectronics, neural engineering, biosensors and wireless communications. He is listed as an inventor on 28 International patents.